Nneka Ufere, MD MSCE
@nnekauferemd.bsky.social
1.5K followers 240 following 35 posts
Transplant Hepatologist at Massachusetts General Hospital. My mission statement: Increase healthcare system empathy for patients with cirrhosis #LiverPal #palliativehepatology #geripal #hpm #hapc #medsky #LiverSky
Posts Media Videos Starter Packs
nnekauferemd.bsky.social
Our question: Can a longitudinal model of specialty aligned inpatient palliative care get more patients happier and healthier to and through transplant 🤔? We will know more at the end of our trial!
nnekauferemd.bsky.social
Today we enrolled our 100th patient into our LiverPal RCT assessing whether longitudinal inpatient palliative care can improve outcomes for hospitalized patients with liver disease and their families. What a Good Friday! #palliativehepatology #livertwitter #liversky
Reposted by Nneka Ufere, MD MSCE
malindalo.bsky.social
Harvard redid its whole homepage to push back against the administration’s demands. I mean, this is just a website but I think it’s kind of a great PR move: www.harvard.edu
Harvard University
Harvard University is devoted to excellence in teaching, learning, and research, and to developing leaders who make a difference globally.
www.harvard.edu
Reposted by Nneka Ufere, MD MSCE
emilymoin.com
How many hospitalized patients need care in the ICU? How many of them survive? What interventions do they receive there?

These are some of the questions I had two years ago while trying to write the "background" section for my masters thesis. But I couldn't find the answers... they did not exist.
nnekauferemd.bsky.social
As hepatologists, there are few things more devastating and very preventable that we see than HBV reactivation. If you are about to start your patient on an immunosuppressant, please keep this figure in mind. #LiverSky #MedSky

https://buff.ly/4gaKqf7
Reposted by Nneka Ufere, MD MSCE
ebtapper.bsky.social
#liversky

Guys. Rifaximin
Reposted by Nneka Ufere, MD MSCE
jturnes.bsky.social
Albumin is the closest thing to a "universal remedy" in cirrhosis

We use it to treat different complications, with good evidence but also with debatable or negative evidence

Excellent analysis by Jonel Trebicka & @ggarciatsao.bsky.social

doi.org/10.1097/hep.0000000000000521

#LiverSky
nnekauferemd.bsky.social
Just created a document titled "R01 SA page".

So it begins. Both nervous but also really excited to think big.

Advice, thoughts, prayers, etc. welcome!

#LiverSky
nnekauferemd.bsky.social
God bless you and this program. Seriously. Thank you for the work you do.
nnekauferemd.bsky.social
Amongst the palliative care domains, it feels like the domain of moral/existential/spiritual needs often gets short shrift unless patients are truly end of life. I wonder if inverting this pyramid to make existential needs the base, and not the peak, opens up a wider world of therapeutic support?
nnekauferemd.bsky.social
In a space in which serious illness, psychological distress, and often addiction can so closely overlap, we have found that using a moral/existential/spiritual frame in serious illness convos and exploring coping is an almost necessary consideration: “How to live a better life with liver disease”
nnekauferemd.bsky.social
I enjoyed reading this - thank you. I’ve been thinking about coping a lot in context of serious illness conversations in hepatology/transplant. In our inpatient LiverPal work, our team talks about how our therapeutic alliance often starts with exploring our patients’ existential/spiritual distress.
Reposted by Nneka Ufere, MD MSCE
jamesheathers.bsky.social
“A donor wanted to give $2 million to my lab, but only wanted to allow a maximum 10 percent to go to indirect cost recovery. And the school declined to receive the $2 million because they wanted at minimum, I believe it was 20 percent.”

www.harvardmagazine.com/2025/01/harv...
Harvard Professors Leaving for Private Sector Research | Harvard Magazine
Three distinguished scientists on leaving academia to advance biomedical research
www.harvardmagazine.com
nnekauferemd.bsky.social
Lets invest in true collaborative care with our palliative care colleagues-this is more than just a triggered referral. Working with my #LiverPal team has been the biggest professional joy of my life. Doing so has required YEARS of longitudinal teamwork and culture change. But its been so worth it.
nnekauferemd.bsky.social
We also need to invest in bidirectional collaboration to grow specialty-aligned palliative care and support our PC clinicians in learning disease-specific symptoms, common treatments, and complications that impact prognosis and outcomes of our patients @releiter.bsky.social

https://buff.ly/3Bw36Yu
nnekauferemd.bsky.social
Authors: "A multipronged effort is needed to meaningfully move the needle...detailed measurement of individual physical, psychological, sociocultural, and other palliative care needs instead of using screening tools that merely identify these unmet domains of needs at a superficial level."

PREACH
nnekauferemd.bsky.social
We need population-specific approaches to symptom management, serious illness conversations, end-of-life care. This requires foundational research. We need to ensure that outcomes that are so often used in PallOnc interventions are appropriate, responsive, and valid in non-cancer populations.
nnekauferemd.bsky.social
And not just ICU but also inpatient/outpatient PC interventions as well. I might go further and say that the copy-and-paste approach from PallOnc trials may not only show no benefit but may have the capacity to cause harm (extra burden of visits, care not aligned with population-specific needs)
nnekauferemd.bsky.social
Thus I could not agree more with the authors: "A heterogeneous array of interventions and outcomes founded on cancer-based models of palliative care (regardless of how they are tailored or targeted) may offer limited benefit above what contemporary ICU care can deliver to patients and families."
nnekauferemd.bsky.social
As a hepatologist who is a proud member of a palliative oncology research lab I'm both inspired by my mentors but have also had a deep realization for years that a "copy-and-paste" approach using PC models developed in cancer cannot, will not, and should not be the way to build #palliativehepatology
nnekauferemd.bsky.social
It is rare that an editorial will make me give a standing ovation to the authors - this one recently published in JAMA Internal Medicine by Kieran Quinn and colleagues did: https://buff.ly/4ggq9FS

@kencovinsky.bsky.social

#palliativehepatology #liversky #hapc
buff.ly
Reposted by Nneka Ufere, MD MSCE
mezzc.bsky.social
How do we apply the new SLD definitions in research? To study outcomes and implement trials for different SLD subtypes, we first need to be able to accurately identify each clinical entity using medical records/registry data.
www.cghjournal.org/article/S154...

@amergastroassn.bsky.social